(Q43623823)

25 November 2017

Propionyl-L-carnitine improves exercise performance and functional status in patients with claudication (English)

1 reference

25 November 2017

1 reference

5

1 reference

25 November 2017

Judith G. Regensteiner

2

object named as

Regensteiner JG

1 reference

25 November 2017

Hiatt WR

1

1 reference

25 November 2017

Creager MA

3

1 reference

25 November 2017

Hirsch AT

4

1 reference

25 November 2017

Olin JW

6

1 reference

25 November 2017

Gorbunov GN

7

1 reference

25 November 2017

Isner J

8

1 reference

25 November 2017

Lukjanov YV

9

1 reference

25 November 2017

Tsitsiashvili MS

10

1 reference

25 November 2017

Zabelskaya TF

11

1 reference

25 November 2017

Amato A

12

1 reference

25 November 2017

language of work or name

English

0 references

publication date

1 June 2001

1 reference

American Journal of Medicine

25 November 2017

1 reference

25 November 2017

110

1 reference

25 November 2017

616-622

1 reference

25 November 2017

8

1 reference

The prevalence of peripheral arterial disease in a defined population

25 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900704-5

Effect of diagnostic criteria on the prevalence of peripheral arterial disease. The San Luis Valley Diabetes Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900704-5

Carnitine metabolism during exercise in patients with peripheral vascular disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900704-5

Exercise training improves functional status in patients with peripheral arterial disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900704-5

Carnitine metabolism during exercise

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900704-5

Increases in walking distance in patients with peripheral vascular disease treated with L-carnitine: a double-blind, cross-over study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900704-5

Superiority of L-propionylcarnitine vs L-carnitine in improving walking capacity in patients with peripheral vascular disease: an acute, intravenous, double-blind, cross-over study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900704-5

European multicenter study on propionyl-L-carnitine in intermittent claudication.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900704-5

The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900704-5

Clinical trials for claudication. Assessment of exercise performance, functional status, and clinical end points. Vascular Clinical Trialists.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900704-5

Cardiorespiratory kinetics during exercise of different muscle groups and mass in old and young

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900704-5

Metabolic Evaluation of the Leg Blood Flow in Claudicating Patients with Arterial Obstructions at Different Levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900704-5

Skeletal muscle carnitine metabolism in patients with unilateral peripheral arterial disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900704-5

Protection of the ischaemic myocardium by L-propionylcarnitine: effects on the recovery of cardiac output after ischaemia and reperfusion, carnitine transport, and fatty acid oxidation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900704-5

Propionyl-L-carnitine dilates human subcutaneous arteries through an endothelium-dependent mechanism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900704-5

Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900704-5

A comparison of cilostazol and pentoxifylline for treating intermittent claudication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900704-5

A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900704-5

Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900704-5

Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900704-5

10.1016/S0002-9343(01)00704-5

7 January 2021

Identifiers

DOI

1 reference

25 November 2017

1 reference